Naperville, IL -- (SBWIRE) -- 02/17/2015 -- Reportstack, provider of premium market research reports announces the addition of Cystic Fibrosis Market in Europe 2015-2019 market report to its offering
[This report is Upcoming for publication on February 18,2015.However you can Pre-order this report.]
About Cystic Fibrosis
Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties related to digestion, and growth anomalies. Cystic fibrosis is one of the most common genetic disorders observed in Caucasian children. Rare diseases are those that affect less than 5 patients per 10,000, as defined in the EU by Rare Disease UK. Cystic fibrosis is therefore classified under rare diseases. The incidence of cystic fibrosis varies between populations. It is significantly less common in Asian and African populations compared to Caucasians (people from Europe, North America, and Australasia), with a marked difference between each country in those regions. Precise data regarding the prevalence of cystic fibrosis in Europe is not available, but it is estimated to be 1 in 8,000-10,000 individuals. Cystic fibrosis is a chronic disease and is usually progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The principal manifestations of cystic fibrosis in patients are chronic bronchitis, pancreatic insufficiency, adolescent diabetes, pancreatitis, male sterility, and very rarely intestinal obstruction or liver cirrhosis. The mortality and morbidity of patients are dependent on the degree of bronchopulmonary involvement.
Analysts forecast the Cystic Fibrosis market in Europe to grow at a CAGR of 35.10 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Cystic Fibrosis market in Europe for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of cystic fibrosis including:
- Small Molecules
- Biologics
Cystic Fibrosis Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers data from Europe; it also covers the market landscape of the Cystic Fibrosis market in Europe and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Vendors
- Actavis
- F. Hoffmann-La Roche
- Gilead Sciences
- Novartis
- Vertex Pharmaceuticals
Other Prominent Vendors
- Abbott
- Anthera Pharmaceuticals
- Arcturus Therapeutics
- Boehringer Ingelheim
- Chiesi Farmaceutici
- Corbus Pharmaceuticals
- Genzyme
- Insmed
- Johnson & Johnson
- Merck Sharp & Dohme
- Neovii Biotech
- Novo Nordisk
- PharmaSwiss
- Pharmaxis
- Proteostasis Therapeutics
- PTC Therapeutics
- United Medical
- Venus Remedies
Market Driver
- Unmet Needs
- For a full, detailed list, view our report
Market Challenge
- High Cost of Treatments
- For a full, detailed list, view our report
Market Trend
- Rise in Public Awareness
- For a full, detailed list, view our report
Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
Complete report is available
http://www.reportstack.com/product/191951/cystic-fibrosis-market-in-europe-2015-2019.html
Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604